

REFERENCES

Bagci P, Ohike N, Dursun N et al. Comparative Analysis of Different Counting Methodologies for Ki-67 in Pancreatic Neuroendocrine Tumors (Abstract). *Modern Pathology* 2012; 25: 441A.

Basturk O, Tang L, Hruban RH et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. *Am J Surg Pathol* 2014; 38: 437-447.

Basturk O, Yang A, Tang LH, et al. The high grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogeneous and includes both well differentiated and poorly differentiated neoplasms. *Am J Surg Pathol* 2015; 39: 683-690.

Bosman FT, Carneiro F, Hruban RH, Theise ND. Neuroendocrine tumors of the GI tract. Lyon: WHO Press 2010.

Hamilton NA, Liu TC, Cavatiao A et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. *Surgery* 2012; 152: 107-113.

Klimstra DS. Pathologic classification of neuroendocrine neoplasms. *Hematol Oncol Clin North Am* 2016; 30:1-19.

Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. *Am J Surg Pathol* 2010; 34: 300-313.

La Rosa S, Marando A, Furlan D, et al. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. *Am J Surg Pathol* 2012; 36: 601-611.

Lowe K, Khithani A, Liu E et al. Ki-67 labeling: a more sensitive indicator of malignant phenotype than mitotic count or tumor size? *J Surg Oncol* 2012; 106: 724-727.

McCall CM, Shi C, Cornish TC et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. *Am J Surg Pathol* 2013; 37: 1671-1677.

Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. *Clin Cancer Res* 2016; 22: 3618-3629.

Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of endocrine pancreas: results from a large international cohort study. *J Natl Cancer Inst* 2012; 104: 764-777.

Rindi G, Kloppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. *Virchows Arch* 2006; 449: 395-401.

Shi C, Klimstra DS. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics. *Semin Diagn Pathol* 2014; 31: 498-511.

Sorbye H, Welin S, Langer SW et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. *Ann Oncol* 2013; 24: 152-160.

Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. *Pancreas* 2010; 39: 799-800.

Tang LH, Basturk O, Sue JJ, et al. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. *Am J Surg Pathol* 2016; 40: 1192-1202.

Tang LH, Gonen M, Hedvat C, et al. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with annual methods. *Am J Surg Pathol* 2012; 36: 1761-1770.

Tang, LH, Untsch Br, Reidy DL, et al. Well differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. *Clin Cancer Res* 2016; 22: 1011-1017.

Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. *Thorac Surg Clin* 2014; 24: 257-266.

Voss SM, Riley MP, Lokhandwala PM, et al. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas. *Am J Surg Pathol* 2015; 39: 13-24.

Woischke C, Schaaf CW, Yang, H, et al. In-depth mutational analysis of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. *Mod Pathol* 2017; 30: 95-103.

Yachida S, Vakiani E, White CM et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. *Am J Surg Pathol* 2012; 36: 173-184.

Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. *Am J Surg Pathol* 2011; 35: 853-860.

Yang Z, Tang LH, Klimstra DS. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current status. *Semin Diagn Pathol* 2013; 30: 186-196.